风湿性疾病与2019冠状病毒病：流行病学与结局
Rheumatic disease and COVID-19: epidemiology and outcomes.
作者信息
Hyrich Kimme L, Machado Pedro M
机构信息
Centre for Epidemiology Versus Arthritis, The University of Manchester, Manchester Academic Health Science Centre, Manchester, UK.
Centre for Rheumatology & Department of Neuromuscular Diseases, University College London, London, UK.
出版信息
Nat Rev Rheumatol. 2021 Feb;17(2):71-72. doi: 10.1038/s41584-020-00562-2.
Since the outset of the COVID-19 pandemic, numerous risk factors for severe disease have been identified. Whether patients with rheumatic diseases, especially those receiving DMARDs, are at an increased risk of SARS-CoV-2 infection or severe COVID-19 disease remains unclear, although epidemiological studies are providing some insight.
自新冠疫情开始以来，已确定了许多导致严重疾病的风险因素。尽管流行病学研究正在提供一些见解，但风湿性疾病患者，尤其是那些正在接受改善病情抗风湿药物治疗的患者，是否面临感染新冠病毒或患重症新冠肺炎的风险增加仍不清楚。
Zotero 插件